Mustang Bio (NASDAQ:MBIO) Shares Down 1.9% – Should You Sell?

Mustang Bio, Inc. (NASDAQ:MBIO) traded down 1.9% during trading on Tuesday . The company traded as low as $1.03 and last traded at $1.03. 20,663 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 66,115 shares. The stock had previously closed at $1.05.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Mustang Bio Trading Down 1.9%

The firm has a market cap of $7.52 million, a price-to-earnings ratio of -3.32 and a beta of 2.10. The company has a fifty day moving average price of $1.14 and a 200-day moving average price of $1.50.

Mustang Bio (NASDAQ:MBIO) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.07) earnings per share for the quarter. As a group, research analysts forecast that Mustang Bio, Inc. will post -35 earnings per share for the current fiscal year.

Mustang Bio Company Profile

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.